Graybug Vision to Report Full-Data Analysis of the 12-month Treatment Phase of its Phase 2b ALTISSIMO Trial
May 05 2021 - 4:05PM
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage
biopharmaceutical company focused on developing transformative
medicines for the treatment of diseases of the retina and optic
nerve, today announced it will host a conference call and webcast
to discuss the full-data analysis of the 12-month treatment phase
of its Phase 2b ALTISSIMO trial on Wednesday, May 12, 2021 at 8
a.m. Eastern time (5 a.m. Pacific time).
The event will be available live by dialing (844) 955-2748
(domestic) and (929) 517-0407 (international) and entering the
conference ID# 5461708 or via webcast from the IR Events &
Presentations page of the Investors and Media section of Graybug’s
website at
https://investors.graybug.vision/news-events/events-presentations.
Following the live event, a replay will be available at the same
location.
About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on
developing transformative medicines for the treatment of diseases
of the retina and optic nerve. The company’s proprietary ocular
delivery technologies are designed to maintain effective drug
levels in ocular tissue for six months and potentially longer,
improving disease management, reducing healthcare burdens and
ultimately delivering better clinical outcomes. Graybug’s lead
product candidate, GB-102, a microparticle depot formulation of the
pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib
malate targeting a six-month or longer dosing regimen, inhibits
multiple neovascular pathways for the intravitreal treatment of
retinal diseases, including wet age-related macular degeneration.
Graybug is also using its proprietary technologies to develop
GB-401, an injectable depot formulation of a beta-adrenergic
blocker prodrug, for primary open-angle glaucoma, with a dosing
regimen of once every six months or longer, and GB-103, a
longer-acting version of GB-102, designed to maintain therapeutic
drug levels in the retinal tissue for 12 months with a single
injection. Founded in 2011 on the basis of technology licensed from
the Johns Hopkins University School of Medicine, Graybug is
headquartered in Redwood City, California. For more information,
please visit www.graybug.vision.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to statements regarding the results of the Phase 2b
ALTISSIMO trial, the company’s clinical pipeline, interactions with
regulatory authorities, its ability to advance GB-102, GB-103,
GB-401, or any future product candidate through clinical
development, its ability to achieve its anticipated milestones
within the timing outlined above or at all, its ability to conduct
planned operations within the evolving constraints arising from the
COVID-19 pandemic, and the timing and results of its clinical
trials. Forward-looking statements are subject to risks and
uncertainties that may cause the company’s actual activities or
results to differ significantly from those expressed in any
forward-looking statement, including risks and uncertainties
described under the heading “Risk Factors” in the company’s most
recent annual and quarterly reports, and the other reports the
company files from time to time with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date of this press release, and the company undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date hereof.
Investor
ContactIR@graybug.vision(650) 487-2409 |
Media
Contactmedia@graybug.vision(404) 384-0067 |
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jul 2023 to Jul 2024